Advertisement
Advertisement
U.S. markets open in 4 hours 22 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Devonian Health Group Inc. (GSD.V)

TSXV - TSXV Real Time Price. Currency in CAD
0.32000.0000 (0.00%)
At close: 01:37PM EST
Advertisement

Devonian Health Group Inc.

360, rue des Entrepreneurs
Montmagny
Québec, QC G5V 4T1
Canada

https://groupedevonian.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Ms. Colette Laurin C.A., CPAInterim CFO, Corp. Sec. & Corp. Controller84kN/AN/A
Dr. Andre P. Boulet Ph.D.Chief Scientific Officer245.25kN/A1959
Mr. Pierre J. MontanaroPres, CEO & DirectorN/AN/AN/A
Mr. Martin Moreau C.F.A., M.Sc.DirectorN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric or duodenal ulcers; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products. The company was incorporated in 2015 and is headquartered in Québec, Canada.

Corporate Governance

Devonian Health Group Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement